IN2012MN02896A - - Google Patents
Download PDFInfo
- Publication number
- IN2012MN02896A IN2012MN02896A IN2896MUN2012A IN2012MN02896A IN 2012MN02896 A IN2012MN02896 A IN 2012MN02896A IN 2896MUN2012 A IN2896MUN2012 A IN 2896MUN2012A IN 2012MN02896 A IN2012MN02896 A IN 2012MN02896A
- Authority
- IN
- India
- Prior art keywords
- hydroxychloroquine
- hcv
- disclosed
- hepatitis
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Methods of treating a hepatitis C virus (HCV) related disease are described herein comprising administering to the subject a therapeutically effective amount of hydroxychloroquine. Therapeutically effective amounts of hydroxychloroquine are disclosed which are sufficient to inhibit HCV-induced autophagy in the subject. An anitviral agent may be co-administered with the hydroxychloroquine. Methods utilizing synergistic combinations of hydroxychloroquine and an antiviral agent are disclosed. Further disclosed are compositions comprising hydroxychloroquine and an antiviral agent as well as hydroxychloroquine and uses thereof for the treatment of a hepatitis C virus (HCV) related disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35801410P | 2010-06-24 | 2010-06-24 | |
PCT/IB2011/052762 WO2011161644A1 (en) | 2010-06-24 | 2011-06-23 | Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012MN02896A true IN2012MN02896A (en) | 2015-06-12 |
Family
ID=44630083
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2896MUN2012 IN2012MN02896A (en) | 2010-06-24 | 2011-06-23 |
Country Status (10)
Country | Link |
---|---|
US (2) | US8987302B2 (en) |
EP (1) | EP2585065A1 (en) |
JP (1) | JP2013529627A (en) |
CN (1) | CN103096891A (en) |
AU (1) | AU2011268498A1 (en) |
BR (1) | BR112012033022A2 (en) |
CA (1) | CA2803093A1 (en) |
IN (1) | IN2012MN02896A (en) |
MX (1) | MX2013000242A (en) |
WO (1) | WO2011161644A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2013000242A (en) | 2010-06-24 | 2014-04-14 | Panmed Ltd | Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent. |
EP2723337A1 (en) | 2011-06-23 | 2014-04-30 | Panmed Ltd. | Treatment of hepatitis c virus |
WO2014122537A2 (en) | 2013-02-05 | 2014-08-14 | Genoscience Sa | Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin |
CN103145811B (en) * | 2013-03-15 | 2014-05-07 | 深圳翰宇药业股份有限公司 | Method for synthesizing Alisporivir |
EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
CN109562107A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Heterocycle degron body for target protein degradation |
CN109562113A (en) | 2016-05-10 | 2019-04-02 | C4医药公司 | Loop coil degron body for target protein degradation |
EP4138831A4 (en) * | 2020-04-20 | 2024-05-15 | Glanis Pharmaceuticals, Inc. | Oral delivery system comprising hydroxychloroquine and/or chloroquine |
JP7477152B2 (en) | 2020-05-12 | 2024-05-01 | 国立大学法人 宮崎大学 | Agent for preventing the onset, inhibiting the progression or treating HTLV-1-related diseases |
JP2024504728A (en) | 2021-01-26 | 2024-02-01 | サイトケアズ (シャンハイ) インコーポレイテッド | Chimeric antigen receptor (CAR) constructs and NK cells expressing CAR constructs |
CN114796126B (en) * | 2022-04-02 | 2023-04-18 | 复旦大学附属中山医院青浦分院(上海市青浦区中心医院) | Hydroxychloroquine sulfate sustained-release microspheres for articular cavity injection and preparation method thereof |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2546658A (en) | 1949-07-23 | 1951-03-27 | Sterling Drug Inc | 7-chloro-4-[5-(n-ethyl-n-2-hydroxyethylamino)-2-pentyl] aminoquinoline, its acid addition salts, and method of preparation |
US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
JP2514950B2 (en) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | Chemically modified protein, its production method and intermediate |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
FR2686899B1 (en) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
US5314894A (en) | 1992-09-15 | 1994-05-24 | Sterling Winthrop Inc. | (S)-(+)-hydroxychloroquine |
KR960705579A (en) | 1993-11-10 | 1996-11-08 | 에릭에스. 딕커 | Improved interferon polymer conjugates |
US5624938A (en) * | 1994-07-18 | 1997-04-29 | The Trustees Of Columbia University In The City Of New York | Use of chloroquine to treat multiple sclerosis |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
US6849254B1 (en) | 1999-04-19 | 2005-02-01 | Schering Corporation | HCV combination therapy |
WO2001081359A1 (en) | 2000-04-20 | 2001-11-01 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
ITBO20020416A1 (en) * | 2002-06-28 | 2003-12-29 | Valpharma Sa | USE OF CHLORINE, HYDROXY-CHLORINE AND 4 AMINO-KINOLINIC DERIVATIVES TO OBTAIN A DRUG FOR THERAPY ANTI RETROVIRAL ACTS |
AU2004273773B2 (en) | 2003-02-21 | 2008-01-24 | Jarrow Formulas, Inc. | Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors |
US7410979B2 (en) | 2003-11-19 | 2008-08-12 | Rigel Pharmaceuticals, Inc. | Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections |
KR101184391B1 (en) | 2004-02-09 | 2013-03-14 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Albumin fusion proteins |
RU2394589C2 (en) | 2004-07-14 | 2010-07-20 | Новартис Аг | Application of cyclosporine and pegylated interferon combination for hepatitis (hcv) treatment |
WO2006109196A2 (en) | 2005-02-04 | 2006-10-19 | Tripep Ab | Transgenic mouse models of hepatitis c virus (hcv) and identification of hcv therapeutics |
US7879797B2 (en) | 2005-05-02 | 2011-02-01 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
US7470664B2 (en) | 2005-07-20 | 2008-12-30 | Merck & Co., Inc. | HCV NS3 protease inhibitors |
WO2007016441A1 (en) | 2005-08-01 | 2007-02-08 | Merck & Co., Inc. | Macrocyclic peptides as hcv ns3 protease inhibitors |
WO2010101649A2 (en) * | 2009-03-05 | 2010-09-10 | Pablo Gastaminza | Sigma 1 receptor inhibition as a novel therapeutical approach against hepatitis c virus infection |
SG182737A1 (en) | 2010-01-27 | 2012-08-30 | Pharma Ltd Ab | Polyheterocyclic compounds highly potent as hcv inhibitors |
MX2013000242A (en) * | 2010-06-24 | 2014-04-14 | Panmed Ltd | Treatment of hepatitis c virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent. |
US8729014B2 (en) | 2010-11-01 | 2014-05-20 | Rfs Pharma, Llc | Specific HCV NS3 protease inhibitors |
EP2723337A1 (en) | 2011-06-23 | 2014-04-30 | Panmed Ltd. | Treatment of hepatitis c virus |
-
2011
- 2011-06-23 MX MX2013000242A patent/MX2013000242A/en not_active Application Discontinuation
- 2011-06-23 EP EP11743355.7A patent/EP2585065A1/en not_active Withdrawn
- 2011-06-23 AU AU2011268498A patent/AU2011268498A1/en not_active Abandoned
- 2011-06-23 IN IN2896MUN2012 patent/IN2012MN02896A/en unknown
- 2011-06-23 JP JP2013516021A patent/JP2013529627A/en active Pending
- 2011-06-23 BR BR112012033022A patent/BR112012033022A2/en not_active IP Right Cessation
- 2011-06-23 WO PCT/IB2011/052762 patent/WO2011161644A1/en active Application Filing
- 2011-06-23 CA CA2803093A patent/CA2803093A1/en not_active Abandoned
- 2011-06-23 CN CN2011800411855A patent/CN103096891A/en active Pending
-
2012
- 2012-12-26 US US13/726,783 patent/US8987302B2/en not_active Expired - Fee Related
-
2013
- 2013-03-15 US US13/836,397 patent/US8575195B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8987302B2 (en) | 2015-03-24 |
MX2013000242A (en) | 2014-04-14 |
WO2011161644A1 (en) | 2011-12-29 |
CA2803093A1 (en) | 2011-12-29 |
US8575195B2 (en) | 2013-11-05 |
JP2013529627A (en) | 2013-07-22 |
EP2585065A1 (en) | 2013-05-01 |
AU2011268498A1 (en) | 2013-01-31 |
US20130202556A1 (en) | 2013-08-08 |
CN103096891A (en) | 2013-05-08 |
BR112012033022A2 (en) | 2016-12-20 |
US20130121965A1 (en) | 2013-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012MN02896A (en) | ||
PH12014502848A1 (en) | Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon | |
MX2012004032A (en) | Compounds for the treatment of hepatitis c. | |
PH12014502847A1 (en) | Combination treatment (eg with abt-072-333) of daas for use in treating hcv | |
MX2013003634A (en) | Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases. | |
MX2020005054A (en) | Combination of two antivirals for treating hepatitis c. | |
MX2009009473A (en) | Compounds for the treatment of hepatitis c. | |
NZ702744A (en) | D-amino acid compounds for liver disease | |
PH12014501133A1 (en) | Compositions and methods for treating hepatitis c virus | |
MY160130A (en) | Hepatitis c virus inhibitors | |
MX2010008148A (en) | Methods of treating viral infections. | |
IN2014MN01547A (en) | ||
MX2012003171A (en) | Novel macrocyclic inhibitors of hepatitis c virus replication. | |
MX2010001416A (en) | Compounds for the treatment of hepatitis c. | |
WO2010085091A3 (en) | Pharmaceutical composition for preventing or treating hepatitis c, comprising the roots extract of platycodon grandiflorum or platycodon grandiflorum saponin components | |
JO3281B1 (en) | Benzofuran Compounds for the Treatment of Hepatitis C Virus Infections | |
TN2011000204A1 (en) | Cycloundecadepsipeptide compounds and use of said compounds as a medicament | |
MX2020011107A (en) | Glycosidase regimen for treatment of infectious disease. | |
WO2014116772A3 (en) | Squaric derivatives for the treatment of hepatitis c | |
WO2012006550A3 (en) | Methods and compositions for treatment of lipogenic virus related conditions | |
WO2011011706A3 (en) | Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents | |
MX2010010061A (en) | Compounds for the treatment of hepatitis c. | |
WO2012040164A3 (en) | Tlr5 ligands, therapeutic methods, and compositions related thereto | |
MX2014014878A (en) | Combination of therapeutic agents for treating hcv infection. | |
NZ602552A (en) | Combination of a macrocyclic inhibitor of hcv, a non-nucleoside and a nucleoside |